PHT Corporation, the leading provider of electronic patient reported outcome (ePRO) solutions today announced a strategic partnership with Entra Health Systems, an international applied healthcare technology company. Together PHT and Entra Health will provide integrated data monitoring technology for the management of clinical trials for the treatment of diabetes and in trials where blood glucose management plays a critical role in the investigation.
“Our goal in launching this solution is to capture time-sensitive data, directly from the patient”
This unique solution for clinical trials combines Entra Health's MyGlucoHealth Wireless blood glucose meter with PHT's ePRO System to create an automated glucose monitoring and ePRO solution.
"It comes down to hard data versus soft data." said Richard Strobridge, CEO of Entra Health Systems. "Clinical Investigators now have direct access to real-time blood glucose data during clinical trials. Patient-related inaccuracies are eliminated. With the MyGlucoHealth Wireless meter we can monitor in real-time not just blood glucose readings, but when and how often patients are testing. Also, MyGlucoHealth offers a higher level of accuracy along with the unique ability to wirelessly upload readings using Bluetooth."
"Our goal in launching this solution is to capture time-sensitive data, directly from the patient," said Phil Lee, President and CEO of PHT. "Research studies have shown hand-written paper log book entries of glucose data contain numerous errors both in transcription and time accuracy. Waiting, downloading, or transcribing this critical data lead to delays and poor clinical trial data quality. Sponsors demand the most accurate real-time data to monitor patient status and evaluate compliance and study effectiveness. The PHT and MyGlucoHealth partnership brings a new level of sophistication to clinical trials that capture blood glucose information."
The integration between PHT's handheld technology and the MyGlucoHealth's Wireless glucometer provides maximum ease of use for patients while improving data flow and ensuring participation and compliance. The system improves safety and rewards researchers with more accurate, real-time data from every clinical trials patient, every day.
Exercise temporarily improves muscle insulin resistance linked to genetic risk for type 2 diabetes